Meningococcal serogroup B vaccines: will they live up to expectations?

References

• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103, 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Wong SH, Lennon DR, Jackson CM et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J.28, 385–390 (2009).
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine28, 2122–2129 (2010).
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis.51, 1127–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine27, 2794–2803 (2009).
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J.29, e71–e79 (2010).
   Web of Science ®Google Scholar
• Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis.7, 504–510 (1985).
   PubMedGoogle Scholar
• Jolley KA, Brehony C, Maiden MCJ. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev.31, 89–96 (2007).
   PubMed Web of Science ®Google Scholar
• Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev. Vaccines9, 1203–1217 (2010).
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14, 195–207; discussion 208–210 (1991).
   PubMedGoogle Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281, 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine7, 325–328 (1989).
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R, F et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7–2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol.14, 65–73 (2007).
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rümke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine17, 2612–2619 (1999).
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EAL, Holmes EC, Feavers IM, Maiden MCJ. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun.72, 5955–5962 (2004).
   PubMed Web of Science ®Google Scholar
• Pettersson A, Kuipers B, Pelzer M et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect. Immun.58, 3036–3041 (1990).
   PubMed Web of Science ®Google Scholar
• Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol.16, 156–162 (2009).
   PubMed Web of Science ®Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29, 1413–1420 (2011).
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Streefland M, van der Ley P et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine28, 4810–4816 (2010).
   PubMed Web of Science ®Google Scholar
• Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun.75, 5434–5442 (2007).
   PubMed Web of Science ®Google Scholar